Coloplast (COLO) AGM 2018 summary
Event summary combining transcript, slides, and related documents.
AGM 2018 summary
23 Oct, 2026Opening remarks and agenda
Søren Meisling, Attorney at Law, was elected Chairman of the General Meeting.
Financial performance review
The Board of Directors’ report on activities and the annual report were adopted.
Board and executive committee updates
Niels Peter Louis-Hansen, Birgitte Nielsen, Carsten Hellmann, Jette Nygaard-Andersen and Jørgen Tang-Jensen were re-elected; Lars Søren Rasmussen was elected as a new Board member.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-appointed as auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Coloplast
- AGM approves DKK 9.00 dividend and governance changes.COLO
AGM 2016 - AGM approved a DKK 17.00 per-share dividend and governance changes alongside Board re-elections.COLOAGM 2019
- AGM approves DKK 19.00 per share in dividends and elects a new Board member.COLOAGM 2021
- FY 2021/22 AGM approved DKK 20 per share in dividends and re-elected the Board.COLOAGM 2022
- Strong organic growth and margin resilience driven by innovation and operational efficiency.COLOInvestor presentation
- 6% organic growth and strong cash flow, but Biologics hit by US reforms and Kerecis impairment.COLOQ3 25/26
- AGM approved a DKK 23.00 per-share dividend and elected Niels B. Christiansen to the Board.COLOAGM 2025
- 8% organic growth, a DKK 22 dividend, and four-platform strategy highlighted the AGM.COLOAGM 2024
- 8% organic growth and 27% EBIT margin before special items, FY guidance unchanged.COLOQ1 24/25